Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 22 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.50 Insider Own58.21% Shs Outstand25.05M Perf Week-0.97%
Market Cap402.35M Forward P/E- EPS next Y-1.25 Insider Trans-0.62% Shs Float10.98M Perf Month7.97%
Income-37.90M PEG- EPS next Q-0.31 Inst Own33.01% Short Float0.57% Perf Quarter75.98%
Sales60.20M P/S6.68 EPS this Y28.71% Inst Trans-1.36% Short Ratio0.71 Perf Half Y240.98%
Book/sh0.62 P/B24.56 EPS next Y7.90% ROA-34.49% Short Interest0.06M Perf Year186.70%
Cash/sh2.33 P/C6.56 EPS next 5Y- ROE-126.82% 52W Range3.01 - 18.15 Perf YTD48.50%
Dividend Est.- P/FCF- EPS past 5Y- ROI-43.82% 52W High-15.65% Beta2.18
Dividend TTM- Quick Ratio5.79 Sales past 5Y7.28% Gross Margin72.06% 52W Low408.64% ATR (14)1.16
Dividend Ex-Date- Current Ratio6.55 EPS Y/Y TTM21.22% Oper. Margin-53.13% RSI (14)53.00 Volatility10.75% 7.09%
Employees167 Debt/Eq4.38 Sales Y/Y TTM37.66% Profit Margin-62.96% Recom1.57 Target Price14.71
Option/ShortYes / Yes LT Debt/Eq4.29 EPS Q/Q41.48% Payout- Rel Volume1.91 Prev Close15.61
Sales Surprise15.48% EPS Surprise30.69% Sales Q/Q47.23% EarningsMar 05 AMC Avg Volume89.41K Price15.31
SMA20-1.78% SMA5020.91% SMA20098.89% Trades Volume171,119 Change-1.92%
Date Action Analyst Rating Change Price Target Change
Jan-30-24Initiated Leerink Partners Outperform $22
Nov-10-23Initiated Cantor Fitzgerald Overweight $11
Aug-24-23Upgrade Morgan Stanley Underweight → Equal-Weight $5 → $6
Feb-22-23Initiated Lake Street Buy $10
Apr-06-22Initiated Wolfe Research Outperform $13
Jan-19-22Downgrade Wells Fargo Overweight → Equal Weight $11
Jan-07-22Downgrade Morgan Stanley Equal-Weight → Underweight $17 → $12
Nov-11-21Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-18-21Initiated Robert W. Baird Outperform $26
May-17-21Initiated Wells Fargo Overweight $25
Feb-15-24 04:05PM
Feb-07-24 03:13AM
Feb-01-24 11:02PM
Jan-08-24 07:03AM
Dec-29-23 09:01PM
07:07AM Loading…
Dec-21-23 07:07AM
Dec-19-23 04:30PM
Dec-04-23 05:07PM
Dec-01-23 08:00AM
Nov-21-23 08:00AM
Nov-07-23 09:45AM
Nov-06-23 04:33PM
Oct-26-23 10:33AM
Oct-17-23 04:05PM
05:01PM Loading…
Oct-16-23 05:01PM
Oct-05-23 01:02AM
Sep-29-23 03:16PM
Sep-20-23 04:05PM
Aug-24-23 04:05PM
Aug-13-23 08:03AM
Aug-08-23 04:03PM
Jul-19-23 04:03PM
Jul-18-23 04:05PM
Jun-28-23 04:03PM
May-24-23 04:05PM
May-05-23 10:13AM
May-04-23 04:05PM
Apr-17-23 04:05PM
04:05PM Loading…
Apr-03-23 04:05PM
Mar-30-23 07:32AM
Mar-06-23 05:52AM
Mar-03-23 06:07AM
Mar-02-23 04:05PM
Feb-10-23 08:00AM
Jan-09-23 04:03PM
Dec-21-22 04:03PM
Nov-30-22 08:00AM
Nov-11-22 05:25AM
Nov-08-22 04:03PM
Nov-04-22 04:03PM
Oct-25-22 04:03PM
Oct-21-22 06:44AM
Oct-11-22 08:00AM
Aug-23-22 04:06PM
Aug-12-22 02:31AM
Aug-11-22 04:02PM
Jul-21-22 04:03PM
May-13-22 03:38PM
May-12-22 04:03PM
May-04-22 08:00AM
Apr-21-22 04:03PM
Mar-21-22 07:49AM
Mar-10-22 08:00PM
Jan-27-22 04:03PM
Jan-11-22 04:03PM
Dec-16-21 07:00AM
Nov-11-21 10:00AM
Nov-10-21 04:03PM
Oct-20-21 04:05PM
Oct-19-21 04:03PM
Sep-20-21 09:34AM
Aug-23-21 04:03PM
Aug-13-21 08:30AM
Aug-12-21 04:03PM
Aug-04-21 08:00AM
Jul-22-21 04:03PM
Jul-03-21 07:07AM
Jun-30-21 08:00AM
Jun-03-21 07:00AM
May-20-21 08:00AM
Apr-26-21 04:05PM
Apr-22-21 04:55PM
Apr-21-21 08:45PM
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morrell MarthaChief Medical OfficerFeb 05Sale15.173,44652,27877,762Feb 06 07:16 PM
Morrell MarthaChief Medical OfficerFeb 02Sale15.0714,143213,12281,208Feb 06 07:16 PM
Morrell MarthaChief Medical OfficerFeb 01Sale15.046639,97195,351Feb 01 09:47 PM
Morrell MarthaChief Medical OfficerJan 31Sale15.081,92328,99096,014Feb 01 09:47 PM
Morrell MarthaChief Medical OfficerJan 30Sale15.1011,262170,00497,937Feb 01 09:47 PM
Morrell MarthaChief Medical OfficerJan 25Sale15.00115109,199Jan 26 06:04 PM
Morrell MarthaChief Medical OfficerJan 24Sale15.0382712,426109,200Jan 26 06:04 PM
Morrell MarthaChief Medical OfficerDec 27Sale10.1213,300134,648110,027Dec 28 05:47 PM
Morrell MarthaChief Medical OfficerDec 26Sale10.001021,020123,327Dec 28 05:47 PM
Morrell MarthaChief Medical OfficerDec 20Sale10.142,73027,695123,429Dec 22 04:21 PM
Morrell MarthaChief Medical OfficerDec 06Sale8.1611,00589,773126,159Dec 07 04:07 PM
KCK LTD.10% OwnerDec 01Sale8.733,24128,2945,593,773Dec 01 09:57 PM
KCK LTD.10% OwnerNov 30Sale8.847,28264,3735,597,014Dec 01 09:57 PM
KCK LTD.10% OwnerNov 29Sale8.725,64449,2165,604,296Dec 01 09:57 PM
KCK LTD.10% OwnerNov 28Sale8.754,68140,9595,609,940Nov 29 05:35 PM
KCK LTD.10% OwnerNov 27Sale8.966,49058,1505,614,621Nov 29 05:35 PM
ORBIMED ADVISORS LLC10% OwnerOct 03Sale9.027006,3144,003,967Oct 04 05:36 PM
ORBIMED ADVISORS LLC10% OwnerOct 02Sale9.087,61469,1354,004,667Oct 04 05:36 PM